

Curriculum Vitae

Name: Timothy J. Daskivich, MD, MSHPM

Business Address: Cedars-Sinai Medical Center
8635 West 3rd Street, Suite 1070W
Los Angeles, California 90048

Business Telephone: 310-423-4700

EDUCATION

Undergraduate: Harvard College, Cambridge, MA (2001)
Bachelor of Arts (AB) in Biochemical Sciences
Magna Cum Laude

Medical School: Harvard Medical School, Boston, MA (2006)
Doctor of Medicine (MD)

Graduate: University of California, Los Angeles (2013)
Masters of Science in Health Policy & Management (MSHPM)

Internship: University of California, Los Angeles (2007)
Department of General Surgery

Residency: University of California, Los Angeles (2012)
Department of Urology

Fellowships: Health Services Research Fellow (2014)
Robert Wood Johnson Clinical Scholars Program
University of California, Los Angeles

Fellow in Urologic Oncology (2015)
Society of Urologic Oncology (SUO) Fellowship Program
University of California, Los Angeles

Licensure: Medical License, State of California (A103871)
DEA (FD1019062)

Board Certification: American Board of Urology Board Eligible
(Passed Step 1, Pending Oral Certification Exam)

PROFESSIONAL

Present Position: Staff Physician I, Division of Urology
Urologic Oncologist, Samuel Oschin Comprehensive Cancer Institute
Director, Health Services Research, Department of Surgery
Cedars Sinai Medical Center

Previous Positions: Clinical Faculty, Urology (7/12–6/15)
West LA Veterans Affairs Medical Center, Los Angeles, CA

Volunteer Clinical Faculty, Urology (12/12–6/15)
Harbor-UCLA Medical Center, Los Angeles, CA

Staff Urologist (7/13–6/14)
Olive View Medical Center, Sylmar, CA

Staff Urologist (7/12–6/14)
Santa Monica-UCLA Medical Center, Santa Monica, CA

Staff Urologist (7/12–8/13)
UCLA Ashe Student Health Clinic, Los Angeles, CA

Professional Activities:

Committee Service: Institutional Review Board, Cedars-Sinai Medical Center (2015-Current)
Resident Wellness Task Force, ACGME (2014-Current)
Chair, ACGME Council for Review Committee Residents (2013-2015)
Resident Director, ACGME Board of Directors (2013-2015)
Awards Subcommittee, ACGME Board of Directors (2013-2015)
Committee on Requirements, ACGME Board of Directors (2013-2015)
American Urological Association Residents Committee (2011-2013)
Resident Member, Residency Review Committee for Urology (2010-2013)
Member, ACGME Council for Review Committee Residents (2010-2013)

Professional Societies: American Urological Association, Member
Society of Urologic Oncology, Candidate Member

Editorial Services: Journal of Clinical Oncology; Cancer; Annals of Internal Medicine;
Archives of Internal Medicine; British Medical Journal; Medical Care;
Journal of the American College of Surgeons; PLoS ONE; BMJ Open;
British Journal of Cancer; Journal of Urology; Urology; European Urology;
BJU International; International Journal of Urology; Urologic Oncology;
Prostate Cancer and Prostatic Diseases; Canadian Journal of Urology;
Clinical Epidemiology; BMC Cancer; European Journal of Clinical
Pharmacology

Honors and Awards: Best Abstract, Society of Urologic Oncology YUO Selection (2014)
Collaborator, RAND Urologic Diseases in America Project (2013-2015)
Best Poster, American Urological Association 2012 Annual Meeting (2012)
Guy Dalla Riva Award for Excellence in Academic Urology (2011)
Resident of the Year in General Surgery (2008)
Karin Grunebaum Oncology Research Fellowship (2005)
Children's Hospital of Oakland Research Fellowship (2002)
MGH Transplantation Biology Research Scholarship (1997)
John Harvard Scholarship for Academic Excellence (2000, 2001)
Harvard College Scholarship for Academic Excellence (1998, 1999)

National Merit Scholarship (1997)

Westinghouse Honors Institute Exam Regional Top 10 Finisher (1997)

Research Grants:

American Cancer Society

Postdoctoral Fellowship (PF CPHPS-124225)

Principal Investigator: Timothy J. Daskivich, MD

Funding Period: 2013 – 2015

Role: Principal Investigator Funding: \$98,000

American Urological Assn Urology Care Foundation Research Scholar

Principal Investigator: Timothy J. Daskivich, MD

Funding Period: 2012 – 2014

Role: Principal Investigator

Funding: \$88,000

Lectures/Presentations:

Invited Presentations

1. "Prostate Cancer: A Story of Overtreatment." Cedars-Sinai Division of Urology CME Conference, Urologic Management of the Aging Patient, Los Angeles, CA, April 2016.
2. "Relevance of Recently Published Data for ATLAS: Life Expectancy, Comorbidity, and Efficacy of Treatment." ATLAS Clinical Trial Team, Janssen Pharmaceuticals, Westwood, CA, March 2016.
3. "Panel Discussion on Physician Wellness." ACGME Annual Education Conference, Washington, DC, February 2016.
4. "Using Surgical Quality Collaboratives to Improve Value of Surgical Care." Cedars-Sinai General Surgery Grand Rounds, Los Angeles, CA, January 2016.
5. "Finding Common Ground on the PSA Screening Debate: Case Selection and Trust between Patients, PCPs, and Specialists." Cedars-Sinai Internal Medicine Grand Rounds, Los Angeles, CA, January 2016.
6. "Precision Medicine in Cancer Care: The Impact of Comorbidity and Life Expectancy on Treatment Choice and Outcomes." Cedars-Sinai Health Services Research Conference, Los Angeles, CA, January 2016.
7. Moderator, Moderated Poster Session, General & Epidemiological Trends & Socioeconomics: Quality of Life Session, American Urological Association 2015 Annual Meeting, Orlando, FL, May 2015.
8. "Prostate Cancer Screening at the West Los Angeles VA." Advanced Nurse Practitioners Annual Conference, West Los Angeles VA, March 2015.
9. "Improving Quality of Decision Making in Men with Early Stage Prostate Cancer." Keynote Speaker, American Cancer Society Cancer Advocacy Network Los Angeles Reception, Los Angeles, CA, November 2014.
10. "Life Expectancy in Treatment Decision Making for Men with Early Stage Prostate Cancer." Urology Grand Rounds, University of California, Irvine, Irvine, CA, November 2014.
11. "Life Expectancy in Treatment Decision Making for Men with Early Stage Prostate Cancer." Urology Grand Rounds, Cedars-Sinai Medical Center, Beverly Hills, CA, September 2014.
12. "Comorbidity, Life Expectancy, and Treatment Decision Making for Men with Early Stage Prostate Cancer." Prostate Cancer DOT Meeting, University of California, Irvine, Irvine, CA, September 2014.
13. "Prostate Cancer Screening and Treatment at the West Los Angeles VA." Department of Internal Medicine Grand Rounds, West Los Angeles VA, January 2014.
14. "The Impact of Age and Comorbidity on Treatment Decision Making in Men with Early-Stage

Prostate Cancer.” Resident and Fellow Research Forum, University of Michigan Health Services Research Symposium, Ann Arbor, MI, September 2012.

15. "Update from the Residency Review Committee." National Resident Forum, American Urological Association 2012 Annual Meeting, Atlanta, GA, May 2012.

Presented Abstracts

1. Wood L, Skarecky DW, Ahlering TA, **Daskivich TJ**. “Operationalizing the National Comprehensive Cancer Network Guidelines for Predicting Life Expectancy in Men with Prostate Cancer.” Moderated Poster Presentation, General & Epidemiological Trends & Socioeconomics: Practice Patterns, Quality of Life, and Shared Decision Making Session, American Urological Association 2016 Annual Meeting, San Diego, May 2016.

2. **Daskivich TJ**, Skarecky DW, Ahlering TA, Freedland SJ. “Comorbidity Status as a Predictor of High-Grade Disease in Men with Prostate Cancer.” Moderated Poster Presentation, Prostate Cancer Epidemiology and Natural History Session, American Urological Association 2016 Annual Meeting, San Diego, May 2016.

3. Tan HJ, **Daskivich TJ**, Shirk J, Filson CS, Litwin MS. “Comorbidity, Disability, and Partial Nephrectomy Use for Older Patients with Stage I Kidney Cancer.” Moderated Poster Presentation, General & Epidemiological Trends & Socioeconomics: Evidence-based Medicine & Outcomes Session, American Urological Association 2016 Annual Meeting, San Diego, May 2016.

4. **Daskivich TJ**, Abedi G, Litwin MS, Kaplan S, Greenfield S. “EMR-Based Comorbidity Assessment Performs Poorly Compared with Physician Assessment in Identifying Major Comorbidities and Predicting Survival.” Poster Session, Academy Health 2015 Annual Meeting, Minneapolis, MN, June 2015.

5. **Daskivich TJ**, Lai J, Dick AW, Setodji CM, Hanley J, Litwin MS, Saigal, CS. “Comparative Effectiveness of Aggressive versus Non-Aggressive Treatment for Men with High-Risk Prostate Cancer and Differing Comorbid Disease Burdens at Diagnosis.” Moderated Poster Presentation, General & Epidemiological Trends & Socioeconomics: Evidence-based Medicine & Outcomes Session, American Urological Association 2015 Annual Meeting, New Orleans, LA, May 2015.

6. **Daskivich TJ**, Tan HJ, Litwin MS, Hu JC. “Treatment Variation by Life Expectancy for Early-Stage Kidney Cancer.” Podium Presentation, General & Epidemiological Trends & Socioeconomics: Evidence-based Medicine & Outcomes Session, American Urological Association 2015 Annual Meeting, New Orleans, LA, May 2015.

7. **Daskivich TJ**, Kwan L, Dash A, Litwin MS. " An Age-Adjusted Comorbidity Index for Prediction of Other-Cause Mortality in Men with Early-Stage Prostate Cancer." Plenary Presentation, Society of Urologic Oncology 2014 Annual Meeting, Young Urologists’ Organization Session, Bethesda, MD, December 2014.

8. **Daskivich TJ**, Lai J, Dick AW, Setodji CM, Hanley J, Litwin MS, Saigal, CS. “Comparative Effectiveness of Aggressive versus Non-Aggressive Treatment for Men with Early-Stage Prostate Cancer and Differing Comorbid Disease Burdens at Diagnosis.” Podium Presentation, General & Epidemiological Trends & Socioeconomics: Evidence-based Medicine & Outcomes Session, American Urological Association 2014 Annual Meeting, Orlando, FL, May 2014.

9. **Daskivich TJ**, Kwan L, Dash A, Litwin MS. “Racial Parity in Tumor Burden, Treatment Choice, and Survival Outcomes in Men with Prostate Cancer in the VA Healthcare System.” Moderated Poster Presentation, General & Epidemiological Trends & Socioeconomics: Evidence-based Medicine & Outcomes Session, American Urological Association 2014 Annual Meeting, Orlando, FL, May 2014.

10. **Daskivich TJ**, Kwan L, Dash A, Greenfield S, Litwin MS. “Less is More: Comorbidity Count vs. Charlson Score to Predict Long-Term, Other-Cause Mortality in Men with Early- Stage Prostate Cancer.” Poster Presentation, Society of Urological Oncology 2013 Annual Meeting, December 2013.

11. **Daskivich TJ**, Kang-Hsien, F, Koyama T, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Stanford JL, Stroup AM, Litwin MS, Penson DF. "Impact of Age, Tumor Risk, and Comorbidity on Competing Risks for Survival in a U.S. Population-Based Cohort of Men with Prostate Cancer." Podium Presentation, Robert Wood Johnson Clinical Scholars Program, November 2013.
12. **Daskivich TJ**, Kang-Hsien, F, Koyama T, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Stanford JL, Stroup AM, Litwin MS, Penson DF. "Impact of Age, Tumor Risk, and Comorbidity on Competing Risks for Survival in a U.S. Population-Based Cohort of Men with Prostate Cancer." Podium Presentation, General & Epidemiological Trends & Socioeconomics: Evidence-based Medicine & Outcomes Session, American Urological Association 2013 Annual Meeting, San Diego, May 2013.
13. **Daskivich TJ**, Chamie K, Kwan L, Dash A, Greenfield S, Litwin MS. "Matching Aggressive Treatment with Tumor Risk in Men with Early Stage Prostate Cancer and Multiple Comorbidities." Moderated Poster Presentation, American Urological Association 2012 Annual Meeting, Atlanta, GA, May 2012.
14. **Daskivich TJ**, Chamie K, Kwan L, Labo J, Palvolgyi R, Dash A, Greenfield S, Litwin MS. "Overtreatment of men with low-risk prostate cancer and significant comorbidity." Podium Presentation, American Urological Association 2011 Annual Meeting, Washington D.C. May 2011.
15. **Daskivich TJ**, Chamie K, Kwan L, Labo J, Dash A, Greenfield S, Litwin MS. "Improved prediction of long-term, other-cause mortality in men with prostate cancer." Podium Presentation, American Urological Association 2011 Annual Meeting, Washington D.C. May 2011.
16. **Daskivich T**, Sadetsky N, Kaplan SH, Greenfield S, Litwin MS. "Comorbidity and mortality in early-stage prostate cancer." Podium Presentation, American Society of Clinical Oncology 2010 Annual Meeting, Chicago, IL. June 2010.
17. **Daskivich, TJ**. "Comorbidity and treatment decision making in men with early-stage prostate cancer." Podium Presentation, Los Angeles Urologic Society, Los Angeles, CA. May 2010.
18. **Daskivich, TJ**, Regan, MM, Kantoff, PW, and Oh, WK. "Prostate specific antigen doubling time (PSA-DT) and velocity (PSA-V) provide independent prognostic information in androgen independent prostate cancer (AIPC) patients receiving chemotherapy." Poster Presentation, American Society of Clinical Oncology 2006 Annual Meeting, Atlanta, GA. June 2006.
19. Regan, MM, **Daskivich, TJ**, Kantoff, PW, and Oh, WK. "Utility of prostate specific antigen doubling time (PSA-DT) at the start of androgen independent prostate cancer (AIPC) and immediately before chemotherapy in predicting efficacy of taxane chemotherapy." Poster Presentation, American Society of Clinical Oncology 2006 Annual Meeting, Atlanta, GA. June 2006.
20. **Daskivich, TJ**. "Linguistic Diversity and AIDS Prevention in Nigeria." Presented to UN Special Envoy on AIDS in Africa. Cambridge, MA. March 2003.

Teaching Activities

1. Small Group Session Moderator, "Genitourinary Evaluation and Examination." David Geffen School of Medicine at UCLA, Third-year medical student curriculum, November 2009 and February 2010.
2. Small Group Teaching Session Instructor, "Kidney Stones: Evaluation and Management." David Geffen School of Medicine at UCLA, Third-year medical student curriculum, December 2010.
3. Discussant, UCLA Department of Urology, Resident In-Service Exam Review, "Urologic Anatomy and Embryology." October 2012.
4. Moderator, Robert Wood Johnson Clinical Scholars Program Journal Club, August 2012, January 2013, and May 2013.
5. Speaker, UCLA Department of Urology, Resident Journal Club, "The Impact of Age and

Comorbidity on Competing Risks for Mortality in Men with Early-Stage Prostate Cancer.” May 2013.

6. Small Group Session Leader, “Malpractice and Tort Reform.” Robert Wood Johnson Clinical Scholars 2013 Annual Conference, November 2013.

7. Small Group Session Moderator, “Genitourinary Evaluation and Examination.” David Geffen School of Medicine at UCLA, Third-year medical student curriculum, November 2014.

PUBLICATIONS

Research Papers (Peer-Reviewed)

A. Research Papers - Peer-Reviewed

1. Woodward JE, Zottola LB, Schaefer AT, Logar AJ, Stazer JK, **Daskivich T**, Peach R, Rao AS. Blockade of the CD28/B7 pathway is required for the establishment of donor cell chimerism in CD40 ligand-deficient recipients. *Transplant Proc.*, 33:115 (2001).
2. **Daskivich T**, Oh WK. Recent Progress in Hormonal Therapy for Advanced Prostate Cancer - 2006. *Current Opinion in Urology*, 16: 173-8 (2006).
3. **Daskivich T**, Oh WK. "Failure of Gonadotropin-Releasing Hormone Agonists With And Without Sterile Abscess Formation At Depot Sites: Insight Into Mechanisms?" *Urology*, 67: 1084 (2006).
4. **Daskivich T**, Regan MM, Oh WK. PSA Doubling Time Calculation - Not as Easy as 1,2,4. *J Urol.*, 176: 1927-37 (2006).
5. Oh WK, Proctor K, Nakabayahi M, Evan C, Tormey LK, **Daskivich T**, Antras L, Smith M, Neary MP, Duh MS. The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. *Cancer*, 109: 1090-6 (2007).
6. **Daskivich TJ**, Regan MM, Oh WK. Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy. *Urology*, 70: 527-31 (2007).
7. Ross RW, Xie W, Regan M, Pomerantz M, Nakabayashi M, **Daskivich TJ**, Sartor O, Taplin ME, Kantoff PW, Oh WK. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason Score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. *Cancer*, 112: 1247- 53 (2008).
8. **Daskivich T**, Sadetsky N, Kaplan SH, Greenfield S, Litwin MS. Severity of comorbidity and non-prostate cancer mortality in men with early-stage prostate cancer. *Arch Intern Med.*, 170: 1396-7 (2010).
9. **Daskivich TJ**, van de Poll-Franse LV, Kwan L, Sadetsky N, Stein DM, Litwin MS. From bad to worse: comorbidity severity and quality of life after treatment for early-stage prostate cancer. *Prostate Cancer Prostatic Dis.*, 13: 320-7 (2010).
10. Morris LF, Park S, **Daskivich T**, Churchill BM, Rao CV, Lei Z, Martinez DS, Yeh MW. Virilization of a female infant by a maternal adrenocortical carcinoma. *Endocr Pract.*, 17:e26-31 (2011).
11. **Daskivich TJ**, Chamie K, Kwan L, Labo J, Dash A, Greenfield S, Litwin MS. Comorbidity and competing risks for mortality in men with prostate cancer. *Cancer*, 117:4642-50 (2011).
12. Palvolgyi R, **Daskivich TJ**, Chamie K, Kwan L, Litwin MS. Bone Scan Overuse in Staging of Prostate Cancer: An Analysis of a Veterans Affairs Cohort. *Urology*, 77:1330-6 (2011).
13. **Daskivich TJ**, Chamie K, Kwan L, Labo J, Palvolgyi R, Dash A, Greenfield S, Litwin MS. Overtreatment of men with low-risk prostate cancer and significant comorbidity. *Cancer*, 117:2058-66 (2011).
14. Chamie K, **Daskivich TJ**, Kwan L, Labo J, Dash A, Greenfield S, Litwin MS. Comorbidities, treatment and ensuing survival in men with prostate cancer. *J Gen Intern Med.*, 27:492-9 (2012).

15. **Daskivich TJ**, Chamie K, Kwan, Labo J, Dash A, Greenfield S, Litwin MS. Improved Prediction of long-term, other-cause mortality in men with prostate cancer. *J Urol.*, 186: 1868-73 (2011).
16. Grady EC, Rosie A, Barr D, Lynch D, Lee KB, **Daskivich T**, Dhand A, Butler PD. Defining scholarly activity in graduate medical education. *J Grad Med Educ.*, 4:558–61 (2012).
17. **Daskivich TJ**, Kang-Hsien, F, Koyama T, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Stanford JL, Stroup AM, Litwin MS, Penson DF. Impact of Age, Tumor Risk, and Comorbidity on Competing Risks for Survival in a U.S. Population-Based Cohort of Men with Prostate Cancer. *Ann Intern Med.*, 158: 709-17 (2013).
18. Chamie K, Litwin MS, Bassett JC, **Daskivich TJ**, Lai J, Hanley JM, Konety BR, Saigal CS; Urologic Diseases in America Project. Recurrence of high-risk bladder cancer: A population-based analysis. *Cancer*, 119:3219-27 (2013).
19. **Daskivich TJ**, Chamie K, Kwan, Dash A, Greenfield S, Litwin MS. Matching Tumor Risk with Aggressiveness of Treatment in Men with Multiple Comorbidities and Early-Stage Prostate Cancer. *Cancer*, 119: 3446-53 (2013).
20. **Daskivich TJ**, Lai J, Dick AW, Setodji CM, Hanley J, Litwin MS, Saigal, CS; Urologic Diseases in America Project. Comparative effectiveness of aggressive versus non-aggressive treatment for men with early-stage prostate cancer and differing comorbid disease burdens at diagnosis. *Cancer*, 120:2432-9 (2014).
21. **Daskivich TJ**, Kwan L, Dash A, Greenfield S, Litwin MS. Weighted vs. Unweighted Charlson score to predict long-term, other-cause mortality in men with early-stage prostate cancer. *Eur Urol.*, 66:1002–9 (2014).
22. **Daskivich TJ**, Lai J, Dick AW, Steodji CM, Hanley JM, Litwin MS, Saigal CS; Urologic Diseases in America Project. Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancer. *Cancer*, 120:3642-50 (2014).
23. **Daskivich TJ**, Kang-Hsien, F, Koyama T, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Stanford JL, Stroup AM, Litwin MS, Penson DF. Prediction of Long-term Other-cause Mortality in Men with Early-stage Prostate Cancer: Results from the Prostate Cancer Outcomes Study. *Urology*, 85: 92–100 (2015).
24. **Daskivich TJ**, Kwan L, Dash A, Litwin MS. Racial Parity in Tumor Burden, Treatment Choice, and Survival Outcomes in Men with Prostate Cancer in the VA Healthcare System. *Prostate Cancer and Prostatic Diseases*, 18:104–9 (2015).
25. Chamie K, Ballon-Landa E, Bassett JC, **Daskivich TJ**, Leventhal M, Deapen D, Litwin MS. Quality of diagnostic staging in patients with bladder cancer: a process-outcomes link. *Cancer*, 121:379–85 (2015).
26. Chamie K, Ballon-Landa E, **Daskivich TJ**, Bassett JC, Lai J, Hanley JM, Konety BR, Litwin MS, Saigal CS; Urologic Diseases in America Project. Treatment and Survival in Patients with Recurrent High-Risk Non-Muscle Invasive Bladder Cancer. *Urol Oncol.*, 33:20.e9–17 (2015).
27. **Daskivich TJ**, Kwan L, Dash A, Litwin MS. An Age-Adjusted Comorbidity Index for Prediction of Other-Cause Mortality in Men with Early-Stage Prostate Cancer. *J Urol.*, 194:73–8 (2015).
28. Hoffman RM, Koyama T, Albertsen PC, Barry MJ, **Daskivich TJ**, Goodman M, Hamilton AS, Stanford JL, Stroup AM, Potosky AL, Penson DF. Self-Reported Health Status Predicts Other-Cause Mortality in Men with Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study. *J Gen Intern Med.*, 30:924–34 (2015).
29. **Daskivich TJ**, Jardine DA, Tseng J, Correa R, Stagg BC, Jacob KM, Harwood JL. Promotion of Wellness and Mental Health Awareness Among Physicians in Training: Perspective of a National, Multispecialty Panel of Residents and Fellows. *J Grad Med Educ.*, 7:143–7 (2015).

B. Research Papers - Peer-Reviewed (In-Press)

1. **Daskivich TJ**, Lai J, Dick AW, Setodji CM, Hanley J, Litwin MS, Saigal, CS; Urologic Diseases in America Project. Calling Into Question the Ten-Year Rule for High-Grade Prostate Cancer:

Comparative Effectiveness of Aggressive versus Non-Aggressive Treatment for High-Grade Disease Across Differing Comorbid Disease Burdens. *Urology*.

2. Halpern J, Sedrakyan A, Hsu WC, Mao J, **Daskivich TJ**, Nguyen P, Golden E, Kang J, Hu JC. Utilization, Complications, and Costs of Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer. *Cancer*.
3. **Daskivich TJ**, Tan HJ, Litwin MS, Hu JC. Life Expectancy and Variation in Treatment for Early Stage Kidney Cancer. *J Urol*.

C. Research Papers - Peer-Reviewed (Submitted)

1. **Daskivich TJ**, Abedi G, Kaplan S, Skarecky D, Ahlering T, Litwin MS, Greenfield S. Accuracy of Electronic Medical Record Comorbidity Data: Implications for Risk Adjustment in Performance Assessment. *Health Services Research*.
2. **Daskivich TJ**, Kim HL. Propublica's Surgeon Scorecard: One Step Forward, Two Steps Back for Prostate Cancer Care? *Urology*.

Research Papers (Non-Peer-Reviewed)

D. Research Papers - Non-Peer-Reviewed

1. **Daskivich TJ**. "Update from the Urology Residency Review Committee. Milestones Project: Establishing Benchmarks for Learning throughout Residency." *AUA News*. Nov 2011, 16(11): 26-27.
2. **Daskivich TJ**. "Demystifying the Site Visit: Perspective of a Resident and Review Committee Member." *ACGME Resident Review*. Winter 2012: 1-3.
3. **Daskivich TJ**. "Update from the Urology Residency Review Committee." *AUA News*. Nov 2012; 17(11): 20-23.
4. **Daskivich TJ**. "Update from the Council of Review Committee Residents: Partners in Moving Toward the Ideal Learning Environment." *ACGME 2014 Annual Report*.
5. **Daskivich TJ**. "Council of Review Committee Residents Providing the Resident Voice in Advancing Educational Policy." *ACGME 2015 Annual Report*.

E. Research Papers - Non-Peer-Reviewed (In-Press)

None

F. Research Papers - Non-Peer-Reviewed (Submitted)

None

Book Chapters

None

Letters to the Editor

1. **Daskivich TJ**, Litwin MS, Saigal C. Reply to Charlson score and competing mortality. *Cancer*, 120:4003–4 (2014).
2. **Daskivich TJ**, Litwin MS, Penson DF. Reply to Effect of age, tumor risk, and comorbidity in a US population-based cohort of men with prostate cancer. *Ann Intern Med.*, 159(5): 370 (2014).

Reviews

None

Editorials

1. **Daskivich TJ**, Belldegrun A. Words of Wisdom: Re: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *Eur Urol.*, 67:816–7 (2015).
2. **Daskivich TJ**. Life Expectancy and Treatment Choice for Men with High-Risk Prostate Cancer. *Eur Urol*, 68:59–60 (2015).
3. **Daskivich TJ**. The Importance of Accurate Life Expectancy Prediction in Men with Prostate Cancer. *Eur Urol*. 2015 Apr 23. Epub ahead of print.